MET and Familial prostate cancer: Watanabe et al. used another c-Met/VEGFR2 dual kinase inhibitor (TAS-115) and showed that the novel inhibitor attenuates FMS-dependent osteoclast differentiation and prostate cancer-induced osteolysis [31,39].